Can Proteomic Profiling Identify Biomarkers and/or Therapeutic Targets for Liver Fibrosis?
( Advances in Treatment of Hepatitis C and B )
Publication series ： Advances in Treatment of Hepatitis C and B
Author： Seyma Katrinli H. Levent Doganay Kamil Ozdil and Gizem Dinler-Doganay
Publisher： IntechOpen
Publication year： 2017
E-ISBN: INT6281565608
P-ISBN(Paperback): 9789535129936
P-ISBN(Hardback): 9789535129943
Subject： R18 Epidemiology and Preventive Medicine;R51 infectious diseases
Keyword： 传染病,流行病学与防疫
Language： ENG
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Can Proteomic Profiling Identify Biomarkers and/or Therapeutic Targets for Liver Fibrosis?
Description
Liver fibrosis is a serious disease that affects around 350–400 million people worldwide. The main approach for fibrosis staging is liver biopsy, which is an invasive procedure that is not endured pretty well by patients. Currently, some serum-based biomarker panels are available for diagnosis and staging of liver fibrosis. Recent high-throughput proteomic studies are also very promising for identification of novel biomarkers for diagnosis and/or treatment of liver fibrosis. We hereby review the application of proteomic profiling studies for identification of fibrosis biomarkers with their advantages and drawbacks.
Chapter